Prime Medicine Inc (PRME)
7.53
+0.45
(+6.36%)
USD |
NASDAQ |
May 20, 16:00
7.55
+0.02
(+0.27%)
Pre-Market: 08:02
Prime Medicine Cash from Investing (Quarterly): -37.03M for March 31, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -37.03M |
| December 31, 2023 | 41.28M |
| September 30, 2023 | -37.77M |
| June 30, 2023 | 27.86M |
| March 31, 2023 | -12.66M |
| Date | Value |
|---|---|
| December 31, 2022 | -13.69M |
| September 30, 2022 | -13.51M |
| June 30, 2022 | -50.79M |
| March 31, 2022 | 30.89M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-50.79M
Minimum
Jun 2022
41.28M
Maximum
Dec 2023
-7.269M
Average
-13.51M
Median
Sep 2022
Cash from Investing (Quarterly) Benchmarks
| Pacific Biosciences of California Inc | -34.14M |
| 10x Genomics Inc | 10.63M |
| Recursion Pharmaceuticals Inc | -6.653M |
| Verve Therapeutics Inc | -41.63M |
| Ginkgo Bioworks Holdings Inc | -12.11M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -67.71M |
| Cash from Financing (Quarterly) | 157.33M |
| Free Cash Flow | -200.61M |
| Free Cash Flow Per Share (Quarterly) | -0.6704 |
| Free Cash Flow to Firm (Quarterly) | -70.03M |
| Free Cash Flow Yield | -28.10% |